Lamivudine/Zidovudine Teva


lamivudine / zidovudine

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Lamivudine/Zidovudine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine/Zidovudine Teva.

This EPAR was last updated on 20/04/2018

Authorisation details

Product details
Lamivudine/Zidovudine Teva
Agency product number
Active substance
  • lamivudine
  • zidovudine
International non-proprietary name (INN) or common name
lamivudine / zidovudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Teva Pharma B.V.
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

18/12/2018 Lamivudine/Zidovudine Teva - EMEA/H/C/001236 - IB/0018


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.

Assessment history

How useful was this page?

Add your rating
2 ratings